Zip-A-Dol is indicated for the symptomatic treatment of cold and flu, mild to moderate muscle pain, post-traumatic pain, fever lasting less than 3 days and mild to moderate headache.
The active ingredient in Zip-A-Dol is ibuprofen.
The Zip-A-Dol is available in a package with 20 hard gelatin capsules.
Ibuprofen is a non-steroidal anti-inflammatory which belongs to the group of propionic acid derivatives with analgesic and antipyretic activity.
For many years, it is used in the treatment of degenerative and extra articular inflammatory forms of rheumatism as well as non-rheumatic swellings and inflammations, with proven therapeutic safety.
Ibuprofen exhibits efficacy similar to other NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis, fever and mild to moderate pain of different etiology, but one of its advantages is to cause less gastrointestinal erosion in relation to other NSAIDs.
Zip-A-Dol capsules is a non prescription medicine containing ibuprofen as active ingredient. Please read the information on the package and the leaflet. In case of doubt or when symptoms persist, consult your doctor or pharmacist. It is indicated for the symptomatic treatment of cold and flu, mild to moderate muscle pain, post-traumatic pain, fever lasting less than 3 days and mild to moderate headache. Precautions: is contraindicated in individuals with known hypersensitivity to ibuprofen or any of its components, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Contraindicated in patients with a history of gastrointestinal bleeding or perforation, related to previous therapy with NSAIDs. Contraindicated in patients with peptic ulcer / active bleeding or peptic ulcer history / recurrent bleeding. Contraindicated in patients with a history of asthma, rhinitis, urticaria, angioneurotic edema or bronchospasm associated with the use of aspirin or other non-steroidal anti-inflammatory. Contraindicated in severe heart failure. Contraindicated in patients with bleeding disorders. It is also contraindicated during the third trimester of pregnancy. Concomitant administration Zip-A-Dol with other NSAIDs, including selective cyclooxygenase-2 inhibitors should be avoided. Should be used with caution in patients with peptic ulcer history or other gastrointestinal diseases, heart disease, hypertension, liver or kidney failure and blood disorders. Bleeding, ulceration, and gastrointestinal perforation: have been reported with all NSAIDs cases of bleeding, ulceration and potentially fatal gastrointestinal perforation, at various stages of treatment, with or without warning symptoms or a history of serious GI events. The co-administer protective agents (eg .: misoprostol or proton pump inhibitors) should be considered in these patients as well as those that require simultaneously taking low dose aspirin or other medicines may increase the risk of ulcer or bleeding, such as corticosteroids, anticoagulants (such as warfarin), selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin. NSAIDs should be used with caution in patients with a history of inflammatory bowel disease (ulcerative colitis, Crohn's disease). Cardiovascular and cerebrovascular effects: have been reported fluid retention and edema associated with NSAID treatment. Hepatic function should be closely monitored in patients presenting with symptoms consistent with liver damage (anorexia, nausea, vomiting, jaundice) and / or develop abnormal liver function (transaminases, bilirubin, alkaline phosphatase, γ-GT). Children: the product should not be used in children under the age of 12 years, in pregnancy and lactation, unless prescribed by the doctor. Zip-A-Dol should be used with caution in patients with systemic lupus erythematosus or other autoimmune diseases, for risk of aseptic meningitis and / or kidney failure. Zip-A-Dol should be discontinued at the first signs of rash, mucosal lesions, or other sign of hypersensitivity. The scientific evidence that drugs that inhibit cyclooxygenase / prostaglandin synthesis, because they affect ovulation, may reduce female fertility is limited. This is reversible upon discontinuation of treatment. Patients presenting with visual impairment during treatment with Zip-A-Dol, should discontinue therapy and undergo eye examination. You should avoid the simultaneous intake of alcohol. Keep out of the reach and sight of children. The product should not be used after the expiration date. Store protected from light, in a dry and cool (below 25 ° C). For more information see the leaflet or contact the marketing authorization holder.
- All
- Biocides
- Cosmetics
- Disp.Médicos
- FoodSupplements
- IPE
- MedicalDevices
- Medicines
